Moleculin Biotech (MBRX) Equity Average (2016 - 2025)
Moleculin Biotech's Equity Average history spans 10 years, with the latest figure at -$6.0 million for Q4 2025.
- Quarterly results put Equity Average at -$6.0 million for Q4 2025, down 141.63% from a year ago — trailing twelve months through Dec 2025 was -$6.0 million (down 141.63% YoY), and the annual figure for FY2025 was $13.1 million, down 37.79%.
- Equity Average for Q4 2025 was -$6.0 million at Moleculin Biotech, up from -$15.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $86.6 million in Q2 2021 to a low of -$15.3 million in Q3 2025.
- The 5-year median for Equity Average is $40.3 million (2023), against an average of $40.4 million.
- The sharpest move saw Equity Average surged 460.19% in 2021, then tumbled 182.85% in 2025.
- Year by year, Equity Average stood at $80.1 million in 2021, then crashed by 30.98% to $55.3 million in 2022, then plummeted by 40.27% to $33.0 million in 2023, then plummeted by 56.68% to $14.3 million in 2024, then tumbled by 141.63% to -$6.0 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at -$6.0 million, -$15.3 million, and $5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.